Every 8-K that ANEW MEDICAL, INC. (WENA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow WENA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WENA filings page.
Klotho Neurosciences entered a Letter Agreement with AAVnerGene to manufacture and develop its KLTO-202 gene therapy candidate using AAVnerGene platform technology. The Company will pay an initial fee of $250,000, additional fees tied to clinical trial stages, and a 2% royalty on revenue from products created using the referenced platform. The agreement is filed as an exhibit to the 8-K and the company furnished a related press release.
The filing discloses the commercial terms but does not quantify expected costs, timelines, or projected revenue impact; it includes customary forward-looking statement cautions.